Drug intelligence / Profile preview

neomycin sulfate + polymyxin b sulfate + hydrocortisone

Development stage
Approved
Lead developer
Glaxo Wellcome
Modality
Small Molecules
Administration
Otic, Topical (ear)
01

Overview

neomycin sulfate + polymyxin b sulfate + hydrocortisone is a combination pharmaceutical product for topical use, most commonly as otic drops, containing **two antibiotics** (neomycin sulfate, polymyxin b sulfate) and **one corticosteroid** (hydrocortisone)[1][2][6]. - **Neomycin sulfate** is an aminoglycoside antibiotic, **polymyxin b sulfate** is a polypeptide antibiotic—both work by inhibiting bacterial protein synthesis (neomycin) and disrupting bacterial cell membranes (polymyxin B), respectively[2][6]. - **Hydrocortisone** is a synthetic corticosteroid that reduces inflammation, swelling, redness, and itching[1][2][6]. The **primary indication** is superficial bacterial infections of the external auditory canal (outer ear infections), including those that may occur after ear surgeries such as mastoidectomy[1][2][6]. This combination is not appropriate for all bacterial infections due to possible resistance, and should not be used if there is a hole or tear in the eardrum[6]. **Formulated as** both a solution and a suspension for otic use (ear drops), each mL typically contains: neomycin sulfate (equivalent to 3.5 mg neomycin base), polymyxin b sulfate (equivalent to 10,000 polymyxin b units), and hydrocortisone (10 mg/1%)[3][6]. **Prescribed only** under medical supervision and for short-term use[1][6]. **Common side effects** include local irritation and, rarely, allergic reactions such as rash, swelling, or hearing loss (ototoxicity)[6]. **Not recommended** for viral, fungal, or mycobacterial infections, or if there is known hypersensitivity to any component[3].

Brand names
Casporyn HCCortisporinCortomycinOti-SonePedioticAntibiotic OticOticair
Other names
neomycin/polymyxin b/hydrocortisoneneomycin+polymyxin b+hydrocortisoneneomycin polymyxin hydrocortisone otictriple antibiotic + steroid oticneomycin sulfate+polymyxin b sulfate+hydrocortisone otic solution/suspension
02

Targets

Bacterial RibosomeGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on neomycin sulfate + polymyxin b sulfate + hydrocortisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neomycin sulfate + polymyxin b sulfate + hydrocortisone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call